​

Editas Medicine (EDIT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

EDIT Stock Forecast

Editas Medicine (EDIT) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $5.00, with a high of $6.00 and a low of $4.00. This represents a 108.33% increase from the last price of $2.40.

$1 $2 $3 $4 $5 $6 High: $6 Avg: $5 Low: $4 Last Closed Price: $2.4

EDIT Stock Rating

Editas Medicine stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (61.54%), 8 Hold (30.77%), 2 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 26 0 2 8 16 Strong Sell Sell Hold Buy Strong Buy

EDIT Price Target Upside V Benchmarks

TypeNameUpside
StockEditas Medicine108.33%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts124
Avg Price Target$6.00$5.50$5.25
Last Closing Price$2.40$2.40$2.40
Upside/Downside150.00%129.17%118.75%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26-83-213
Sep, 26-74-213
Aug, 26-64-212
Jul, 26-74-213
Jun, 26-74-213
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 08, 2026Wells Fargo$6.00$2.81113.52%150.00%
Sep 23, 2026Debjit ChattopadhyayGuggenheim$5.00$2.9271.23%108.33%
May 05, 2026Chardan Capital$4.00$3.0431.58%66.67%
Mar 09, 2026Robert W. Baird$6.00$2.32158.62%150.00%
Nov 05, 2024Gena WangBarclays$5.00$3.1260.26%108.33%
Oct 23, 2024Yanan ZhuWells Fargo$9.00$3.29173.56%275.00%
Oct 22, 2024Joel BeattyRobert W. Baird$10.00$3.29203.95%316.67%
Aug 08, 2024Joon LeeTruist Financial$12.00$4.24183.02%400.00%
Aug 08, 2024Greg HarrisonBank of America Securities$15.00$4.21256.29%525.00%
May 30, 2024Liisa BaykoEvercore ISI$7.00$5.1037.25%191.67%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 08, 2026Wells FargoSector PerformOverweightupgrade
Sep 23, 2026GuggenheimBuyupgrade
May 27, 2026Cowen & Co.BuyBuyhold
Mar 09, 2026Cowen & Co.BuyBuyhold
Aug 15, 2025H.C. WainwrightBuyBuyhold
Apr 28, 2025H.C. WainwrightBuyinitialise
Nov 06, 2024Evercore ISIOutperformupgrade
Nov 05, 2024OppenheimerPerformPerformhold
Nov 05, 2024BarclaysMixedMixedhold
Nov 04, 2024RBC CapitalSector PerformSector Performhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.85$-3.21$-2.02$-2.88$-1.80---
Avg Forecast$-3.01$-3.05$-2.40$-2.70$-1.39$-1.23$-1.37$-1.27
High Forecast$0.48$0.64$-1.60$-2.32$-0.89$-0.62$-0.97$-0.33
Low Forecast$-7.80$-11.34$-2.69$-3.04$-2.41$-1.83$-1.75$-4.54
Surprise %-5.32%5.25%-15.83%6.67%29.50%---

Revenue Forecast

$0 $19M $38M $57M $76M $95M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$25.54M$19.71M$78.12M$32.31M----
Avg Forecast$17.41M$16.59M$21.99M$34.36M$8.72M$5.43M$13.20M$30.22M
High Forecast$38.70M$51.31M$50.85M$53.91M$26.01M$16.20M$39.37M$90.13M
Low Forecast$1.88M$1.15M$12.42M$3.72M$3.74M$2.33M$5.67M$12.97M
Surprise %46.75%18.84%255.28%-5.95%----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-192.50M$-220.43M$-153.22M$-237.09M$-160.06M---
Avg Forecast$-203.25M$-226.29M$-153.22M$-210.57M$-144.63M$-93.01M$-103.61M$-96.36M
High Forecast$-162.60M$-181.04M$-122.58M$-176.38M$-67.63M$-46.86M$-73.91M$-24.86M
Low Forecast$-243.89M$-271.55M$-183.86M$-230.88M$-183.12M$-139.15M$-133.32M$-344.75M
Surprise %-5.29%-2.59%-12.59%10.67%---

EDIT Forecast FAQ

Is Editas Medicine stock a buy?

Editas Medicine stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 8 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Editas Medicine is a favorable investment for most analysts.

What is Editas Medicine's price target?

Editas Medicine's price target, set by 26 Wall Street analysts, averages $5 over the next 12 months. The price target range spans from $4 at the low end to $6 at the high end, suggesting a potential 108.33% change from the previous closing price of $2.4.

How does Editas Medicine stock forecast compare to its benchmarks?

Editas Medicine's stock forecast shows a 108.33% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Editas Medicine over the past three months?

  • October 2026: 0% Strong Buy, 61.54% Buy, 23.08% Hold, 0% Sell, 15.38% Strong Sell.
  • September 2026: 0% Strong Buy, 53.85% Buy, 30.77% Hold, 0% Sell, 15.38% Strong Sell.
  • August 2026: 0% Strong Buy, 50.00% Buy, 33.33% Hold, 0% Sell, 16.67% Strong Sell.

What is Editas Medicine’s EPS forecast?

Editas Medicine's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.23, marking a -31.67% decrease from the reported $-1.8 in 2025. Estimates for the following years are $-1.37 in 2027, and $-1.27 in 2028.

What is Editas Medicine’s revenue forecast?

Editas Medicine's average annual revenue forecast for its fiscal year ending in December 2026 is $5.43M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $13.2M, and $30.22M for 2028.

What is Editas Medicine’s net income forecast?

Editas Medicine's net income forecast for the fiscal year ending in December 2026 stands at $-93.007M, representing a -41.89% decrease from the reported $-160M in 2025. Projections indicate $-104M in 2027, and $-96.362M in 2028.